Pre‑biologic/biosimilar Screen Panel, HCV/HBV with Reflexes and QFT 1 Tube
Also known as: Rituxan, Rituximab, Remicade, Infliximab, Tuberculosis
Use
This panel is used to screen patients prior to initiation of biologic or biosimilar therapies. It provides comprehensive infectious disease screening, including Hepatitis C (HCV) antibody with reflex to HCV RNA and genotyping if positive; Hepatitis B virus (HBV) markers with reflex confirmation; and latent tuberculosis testing via QuantiFERON‑TB Gold Plus (1‑tube). Such pre‑therapy infection screening helps mitigate the risk of reactivation or exacerbation during immunosuppressive treatment.
Special Instructions
Not provided.
Limitations
Not provided.
Methodology
Multiplex Protein Panel
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Not provided.
Other tests from different labs that may be relevant
